Vir Biotechnology, Inc. (NASDAQ:VIR) Holdings Increased by Handelsbanken Fonder AB

Handelsbanken Fonder AB increased its stake in Vir Biotechnology, Inc. (NASDAQ:VIR) by 70.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,500 shares of the company’s stock after acquiring an additional 9,300 shares during the period. Handelsbanken Fonder AB’s holdings in Vir Biotechnology were worth $226,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Hudson Bay Capital Management LP boosted its position in shares of Vir Biotechnology by 1,975.0% during the 3rd quarter. Hudson Bay Capital Management LP now owns 207,500 shares of the company’s stock valued at $1,944,000 after purchasing an additional 197,500 shares in the last quarter. Barclays PLC lifted its stake in Vir Biotechnology by 124.6% during the third quarter. Barclays PLC now owns 412,161 shares of the company’s stock valued at $3,863,000 after purchasing an additional 228,634 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its holdings in Vir Biotechnology by 582.9% during the third quarter. Schonfeld Strategic Advisors LLC now owns 162,128 shares of the company’s stock worth $1,519,000 after buying an additional 138,387 shares in the last quarter. GSA Capital Partners LLP acquired a new position in Vir Biotechnology in the third quarter worth approximately $1,098,000. Finally, Vanguard Group Inc. increased its holdings in shares of Vir Biotechnology by 9.4% in the third quarter. Vanguard Group Inc. now owns 11,200,666 shares of the company’s stock valued at $104,950,000 after buying an additional 960,302 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, March 15th. JPMorgan Chase & Co. increased their price target on Vir Biotechnology from $10.00 to $12.00 and gave the company a “neutral” rating in a research report on Friday. Finally, Needham & Company LLC restated a “buy” rating and set a $15.00 price objective on shares of Vir Biotechnology in a report on Friday. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.63.

Insider Buying and Selling

In related news, CEO Backer Marianne De sold 72,995 shares of the company’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $9.46, for a total transaction of $690,532.70. Following the completion of the sale, the chief executive officer now directly owns 678,457 shares of the company’s stock, valued at approximately $6,418,203.22. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Vir Biotechnology news, CFO Sung Lee sold 6,008 shares of Vir Biotechnology stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $9.89, for a total value of $59,419.12. Following the transaction, the chief financial officer now directly owns 100,492 shares of the company’s stock, valued at approximately $993,865.88. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Backer Marianne De sold 72,995 shares of the company’s stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $9.46, for a total value of $690,532.70. Following the transaction, the chief executive officer now owns 678,457 shares of the company’s stock, valued at $6,418,203.22. The disclosure for this sale can be found here. In the last ninety days, insiders sold 152,831 shares of company stock worth $1,525,844. 15.60% of the stock is currently owned by insiders.

Vir Biotechnology Stock Up 13.2 %

Vir Biotechnology stock opened at $10.39 on Friday. Vir Biotechnology, Inc. has a 12 month low of $7.61 and a 12 month high of $27.48. The company’s fifty day simple moving average is $9.82 and its 200-day simple moving average is $9.59. The stock has a market cap of $1.40 billion, a P/E ratio of -2.26 and a beta of 0.47.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Thursday, May 2nd. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.51. The firm had revenue of $56.38 million for the quarter, compared to the consensus estimate of $11.71 million. Vir Biotechnology had a negative return on equity of 34.92% and a negative net margin of 713.69%. The business’s quarterly revenue was down 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.06) earnings per share. On average, equities research analysts expect that Vir Biotechnology, Inc. will post -4.04 earnings per share for the current fiscal year.

About Vir Biotechnology

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.